Furthermore, in MCL, a robust synergy was observed between the HSP90 inhibitor, LAM-003 and venetoclax in FLT3-ITD AML cells, a particularly aggressive and resistant cell type [148]. The gene discussed is HSP90AB1; the disease is mantle cell lymphoma.